Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
Bioxytran (OTCQB:BIXT) announced on Nov 13, 2025 that Independent Research initiated coverage of the stock and published a report highlighting clinical and corporate updates.
Key clinical data for lead candidate ProLectin-M: 88% viral clearance by day 3 and 100% by day 7 in mild-to-moderate COVID-19, with no serious adverse events reported. The drug targets the galectin fold and is positioned as a potential broad-spectrum antiviral.
Pipeline focus includes ambulatory stroke candidate BXT-25 aimed at expanding the 3-hour treatment window. The report flags funding as the primary risk and notes >50% insider ownership and active pursuit of strategic partnerships.
Bioxytran (OTCQB:BIXT) ha annunciato il 13 novembre 2025 che Independent Research ha avviato la copertura del titolo e ha pubblicato un rapporto che evidenzia aggiornamenti clinici e aziendali.
Dati clinici chiave per il candidato principale ProLectin-M: l’eliminazione virale all’88% entro il giorno 3 e 100% entro il giorno 7 in COVID-19 da lieve a moderato, con assenza di eventi avversi gravi riportati. Il farmaco mirata la piega della galectina ed è presentato come potenziale antivirale a ampio spettro.
L’attenzione sul pipeline include anche il candidato per ictus ambulatorio BXT-25, finalizzato ad ampliare la finestra di trattamento di 3 ore. Il rapporto segnala il finanziamento come rischio principale e segnala una proprietà di oltre 50% da parte degli insider e una ricerca attiva di partnership strategiche.
Bioxytran (OTCQB:BIXT) anunció el 13 de noviembre de 2025 que Independent Research inició la cobertura de la acción y publicó un informe que destaca actualizaciones clínicas y empresariales.
Datos clínicos clave para el candidato principal ProLectin-M: 88% de eliminación viral para el día 3 y 100% para el día 7 en COVID-19 leve a moderado, sin eventos adversos graves reportados. El fármaco apunta a la estructura de galectina y se presenta como un posible antiviral de amplio espectro.
El enfoque de la cartera incluye el candidato para accidente cerebrovascular ambulatorio BXT-25, destinado a ampliar la ventana de tratamiento de 3 horas. El informe señala financiamiento como el principal riesgo y destaca una propiedad de >50% de insiders y la búsqueda activa de alianzas estratégicas.
Bioxytran (OTCQB:BIXT)은 2025년 11월 13일에 Independent Research가 주가 커버리지를 시작했고 임상 및 기업 업데이트를 강조하는 보고서를 발표했다고 발표했습니다.
주요 후보 물질 ProLectin-M의 임상 데이터: 경증~중등도 COVID-19에서 일 3일째까지 88%의 바이러스 제거와 일 7일째까지 100%를 보였으며 심각한 이상반응은 보고되지 않음입니다. 이 약물은 갈렉틴 접힘을 표적으로 하며 광범위 스펙트럼 항바이러스로서의 가능성이 제시됩니다.
파이프라인의 초점은 3시간 치료 창을 확장하려는 외래성 뇌졸중 후보물질 BXT-25를 포함합니다. 보고서는 자금 조달을 주요 위험으로 지적하고 50% 이상 내부자 보유 및 전략적 파트너십의 적극적 추구를 언급합니다.
Bioxytran (OTCQB:BIXT) a annoncé le 13 novembre 2025 que Independent Research a initié une couverture de l’action et publié un rapport mettant en avant des mises à jour cliniques et corporatives.
Données cliniques clés pour le candidat principal ProLectin-M : 88% d’élimination virale au jour 3 et 100% au jour 7 chez les patients COVID-19 léger à modéré, avec aucun événement indésirable grave signalé. Le médicament cible la pliure de la galectine et est présenté comme un antiviral à large spectre potentiel.
L’axe de développement comprend le candidat pour AVC ambulatoire BXT-25, visant à étendre la fenêtre de traitement de 3 heures. Le rapport met en avant le financement comme principal risque et note une détention d’actions par les initiés de >50 % et la poursuite active de partenariats stratégiques.
Bioxytran (OTCQB:BIXT) gab am 13. November 2025 bekannt, dass Independent Research eine Abdeckung der Aktie aufgenommen hat und einen Bericht veröffentlicht hat, der klinische und unternehmerische Updates hervorhebt.
Wesentliche klinische Daten für den Leitkandidaten ProLectin-M: 88% Virenreduktion bis Tag 3 und 100% bis Tag 7 bei mild bis moderat verlaufendem COVID-19, mit keinen schweren Nebenwirkungen berichtet. Das Medikament zielt auf die Galektin-Faltung ab und wird als potenzieller Breitbandantiviraler Wirkstoff positioniert.
Der Pipeline-Fokus umfasst den ambulanten Schlaganfallkandidaten BXT-25, der darauf abzielt, das 3-Stunden-Behandlungsfenster zu erweitern. Der Bericht stuft Finanzierung als primäres Risiko ein und vermerkt eine Insider-Besitzquote von über 50% sowie die aktive Verfolgung strategischer Partnerschaften.
Bioxytran (OTCQB:BIXT) أعلن في 13 نوفمبر 2025 أن Independent Research بدأ تغطية السهم ونشر تقريراً يبرز تحديثات سريرية وشركاتية.
بيانات سريرية رئيسية للمترشح الرئيسي ProLectin-M: إزالة الفيروس بنسبة 88% بنهاية اليوم 3 و 100% بنهاية اليوم 7 في COVID-19 الخفيف إلى المتوسط، مع عدم الإبلاغ عن أحداث جانبية خطيرة. الدواء يستهدف طيّة الغالكتين ويُطرح كعلاج مضاد فيروسات واسع الطيف محتمل.
يركز خط الأنابيب على المترشح للسكتة الدماغية القابلة للمتابعة BXT-25 بهدف توسيع نافذة العلاج إلى 3 ساعات. كما يشير التقرير إلى التمويل كخطر رئيسي ويذكر امتلاك الداخلين لأكثر من 50% ونشاط السعي وراء شراكات استراتيجية.
- ProLectin-M viral clearance: 88% by day 3
- ProLectin-M viral clearance: 100% by day 7
- Insider ownership exceeding 50% aligned with shareholders
- Primary risk: insufficient funding could delay clinical programs
- Company has struggled to raise funds over two years, relying on insider support
BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer’s, and viral infections is pleased to announce the initiation of coverage of its stock by Independent Research, a global equity research firm specializing in micro-cap and small-cap public companies.
Highlights from the report include:
Eliminating Viral Threats from the Pandemic Level to the Common Cold
Bioxytran’s lead candidate, ProLectin-M, demonstrated rapid viral clearance in mild-to-moderate COVID-19 patients—
Overcoming the Biggest Challenge in Stroke Treatment
The Company continues to focus on developing BXT-25, the only ambulatory treatment which can overcome the problem of a minuscule 3-hour treatment window available for victims of stroke. The Company could reduce the time to treatment by a significant margin. An approval in indication could translate into a majority share of the multibillion-dollar global stroke market.
Strong Insider Alignment
Over
Strategic Partnership Potential
Bioxytran’s platform technologies—virology, oxygen transport, and cancer metastasis—offer multiple entry points for big pharma collaborations. The company is actively seeking strategic partners to accelerate development and commercialization.
The full research report is available http://tinyurl.com/5eb6dftt
INVESTMENT VIEW:
Bioxytran is considered a speculative investment, yet significantly de-risked due to its strong galectin science and robust clinical efficacy demonstrated in multiple randomized controlled trials—with no serious adverse events. The primary risk is funding. Without sufficient capital, clinical development of ProLectin-M and BXT-25 may be delayed. The company has struggled to raise funds over the past two years and has relied heavily on insider support. Bioxytran’s platform technologies—virology, oxygen transport, and cancer metastasis—are highly differentiated and could attract strategic partnerships or licensing deals. Its market cap is a fraction of comparable antiviral platform companies, suggesting substantial upside if funding or collaboration is secured. Insider ownership exceeds
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What did Independent Research report about Bioxytran (BIXT) on November 13, 2025?
What viral clearance results did ProLectin-M show in the Independent Research report for BIXT?
How does the report describe Bioxytran's (BIXT) stroke candidate BXT-25?
What is the main investment risk for Bioxytran (BIXT) cited in the report?
How much insider ownership does Bioxytran (BIXT) have according to the report?
